RECORDATI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.8 EUR | +0.89% |
|
+0.10% | +4.03% |
| 10/05 | Futures bullish; Mib restarts at 34,300 level | AN |
| 09/05 | Mib up, Nexi and Prysmian good after accounts | AN |
ETFs positioned on Recordati
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +5.79% | - | |
| 0.00% | 0 M€ | +5.63% | - | |
| 0.00% | 0 M€ | +3.50% | - | |
| 0.00% | 0 M€ | +2.80% | - | |
| 0.00% | 0 M€ | +3.63% | - | |
| 0.00% | 0 M€ | +2.72% | - | |
| 0.00% | 0 M€ | +0.32% | - | |
| 0.00% | 0 M€ | +0.50% | - | |
| 0.00% | 0 M€ | 0.00% | - | |
| 0.00% | 0 M€ | -2.25% | - | |
| 0.00% | 0 M€ | -2.58% | - | |
| 0.00% | 0 M€ | -3.22% | - |
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.;
- medicines for rare diseases (32.1%).
Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
Sector
Pharmaceuticals
Calendar
20/05/2024
- Final dividend
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
50.8
EUR
Average target price
52.24
EUR
Spread / Average Target
+2.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.03% | 11.28B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- REC Stock
- Funds and ETFs Recordati
